Aurobindo Pharma Limited Q4 results show a revenue rise from 6499.8 to 6607.9 crores, a 1.66% increase in growth. EPS also rise from ₹8.38 to ₹8.64, up by 3.10%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Aurobindo Pharma Ltd. shared its Q4 results on Saturday. They earned 6607.9 crores in revenue this quarter, but that’s higher than the 6499.8 crores they made last quarter. The company’s growth increased by 1.66 percent when comparing the two quarters.
In terms of profits, the company’s Consolidated PAT (Profit After Tax) for this quarter was 506.3 crores, up from 491.3 crores in the previous quarter. Their quarter-to-quarter growth inclined by 3.05 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹8.64, which is an increase of 3.10% from the ₹8.38 EPS in the previous quarter.
Also read: ☞ ” BHEL Q4FY23 Results: Consolidated PAT Rose to Rs 611 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 24855.4 crores this year (2023), which is 5.97 percent higher than last year’s total revenue of 23455.5 crores.
This year’s Consolidated PAT (Profit After Tax) is 1927.5 crores, which is also 27.21% lower than last year’s PAT of 2648.2 crores.
The EPS (Earnings Per Share) for this year is ₹32.90, which is 27.20% less than the EPS of ₹45.19 earned last year.
Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Aurobindo Pharma:
Aurobindo Pharma Limited, headquartered in HITEC City, Hyderabad, India, is a multinational pharmaceutical manufacturing company from India. The company specializes in producing generic pharmaceuticals and active pharmaceutical ingredients.
Download the Full PDF of Q4 Results: Click Here
For more of the Latest News, Click Here
One thought on “Aurobindo Pharma Q4FY23 Results: Consolidated PAT Rose to Rs 506.3 Cr”